Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25

Receives 3 final and 2 tentative product approvals thus far in Q1FY25

Alembic Pharmaceuticals posts Q4 FY24 PAT at Rs. 178.21 Cr

The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024

WACKER expands production capacity for biopharmaceuticals in San Diego

Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA

Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility

With this, for all our USFDA facilities, EIRs are in place

Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals

Eugia Pharma Specialities receives 7 observations from USFDA for Unit II

Jubilant Pharmova announces completion of USFDA audit of Radiopharmaceuticals manufacturing facility at Montreal

The USFDA has issued 5 observations pursuant to the completion of audit

Bafna Pharmaceuticals inaugurates Quality Control Lab

The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes

Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines

Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry

UroGen Pharma files patent infringement action against Teva Pharmaceuticals